Uterine Fibroids: The Diagnoses Most Often Missed, Confused, or Delayed

Why Fibroids Get Missed So Often

Fibroids are extraordinarily common. ACOG estimates that up to 80 percent of women will develop uterine leiomyomas by age 50, yet symptoms are frequently normalized, misattributed to "heavy periods," or blamed on a different condition entirely. Several structural problems drive the gap between onset and diagnosis.

First, heavy menstrual bleeding is the symptom women most often report. Clinicians trained to think of heavy bleeding as a spectrum, rather than a red flag requiring imaging, may offer hormonal contraception without ever ordering an ultrasound. Second, the symptom list for fibroids overlaps with at least six other gynecologic and metabolic conditions. Third, significant racial and socioeconomic disparities shape who gets referred and when.

A 2022 analysis in the American Journal of Obstetrics and Gynecology found that Black women waited a median of 4.4 years from symptom onset to fibroid diagnosis, compared with 2.6 years for white women. That gap is not explained by symptom severity alone. It reflects documented differences in how pain and bleeding are assessed across patient populations.

The Symptom Overlap Problem

Fibroids produce symptoms through two distinct mechanisms: hormonal sensitivity that drives heavy bleeding, and mass effect that causes pressure on adjacent organs. Both mechanisms are shared, at least partially, by multiple other conditions. That is why a symptom checklist alone cannot confirm a fibroid diagnosis.

When Imaging Is Still Skipped

Transvaginal ultrasound is the standard first-line imaging tool for suspected fibroids, with sensitivity around 90 percent for intramural and subserosal lesions. The problem is that transvaginal ultrasound misses small submucosal fibroids and cannot reliably distinguish fibroids from adenomyosis in a diffusely enlarged uterus. ACOG Practice Bulletin 96 recommends saline-infusion sonography or MRI when ultrasound findings are inconclusive or when submucosal disease is suspected. That escalation does not always happen.

The Six Conditions Most Commonly Confused With Fibroids

Adenomyosis: The Most Frequent Mix-Up

Adenomyosis occurs when endometrial glands and stroma grow into the myometrium. The uterus enlarges, becomes globular, and bleeds heavily during menstruation. Sound familiar? That is because the clinical picture mirrors fibroids closely enough that the two were frequently diagnosed only at hysterectomy before MRI became routine.

A 2020 meta-analysis in Fertility and Sterility estimated that adenomyosis co-exists with fibroids in 35 to 55 percent of cases, which means a clinician who finds fibroids on ultrasound may stop looking and miss a concurrent adenomyosis diagnosis. The reverse is equally true: a woman told she has adenomyosis may actually have diffuse small fibroids.

The clearest distinguishing features are on MRI. Adenomyosis shows junctional zone thickening (greater than 12 mm is diagnostic), while fibroids appear as discrete, well-circumscribed lesions with a pseudocapsule. If your ultrasound shows a bulky, heterogeneous uterus without clearly defined nodules, ask specifically whether an MRI has been considered.

Endometriosis: Different Disease, Similar Chief Complaint

Endometriosis involves endometrial-like tissue outside the uterus, most commonly on the ovaries, fallopian tubes, and pelvic peritoneum. Its cardinal symptoms are dysmenorrhea, deep dyspareunia, and cyclical pelvic pain. Fibroids, particularly submucosal ones, also cause severe dysmenorrhea and can cause pelvic pain between periods if large enough to compress adjacent structures.

The average diagnostic delay for endometriosis in the United States is 7 to 10 years, and it is not rare for a woman to receive a fibroid diagnosis on pelvic ultrasound while concurrent endometriosis goes undetected, because standard ultrasound does not reliably visualize peritoneal implants. Laparoscopy remains the gold standard for endometriosis diagnosis.

Women reporting pain that worsens specifically in the days before and during menstruation, pain with intercourse, or cyclical bowel or bladder symptoms alongside heavy bleeding should have endometriosis explicitly considered, not just assumed to be fibroid-related.

Polycystic Ovary Syndrome: The Hormonal Masquerade

PCOS is primarily a disorder of androgen excess and ovulatory dysfunction. Its heavy, irregular, or prolonged bleeding comes from anovulation and unopposed estrogen, not from uterine mass effect. A woman with PCOS may have irregular but very heavy periods that prompt a pelvic ultrasound; if that ultrasound finds incidental small fibroids, the fibroids may be blamed for the bleeding even when the real driver is anovulatory endometrial buildup.

The Rotterdam criteria require two of three features for PCOS diagnosis: oligo-ovulation or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. None of these features are evaluated during a routine fibroid workup unless the clinician specifically orders androgen levels, LH/FSH ratio, and antral follicle count.

If your periods are irregular (cycles shorter than 21 days or longer than 35 days) and you have been told you have fibroids, ask whether PCOS labs have been drawn.

Endometrial Polyps: Smaller, Softer, Easily Overlooked

Endometrial polyps are focal overgrowths of endometrial tissue attached to the uterine wall by a stalk. They cause heavy or irregular bleeding and, in larger cases, a sensation of pelvic fullness. Standard grayscale transvaginal ultrasound can miss polyps, particularly in the secretory phase when the endometrium is thicker and a polyp blends in.

Saline-infusion sonography (SIS) improves polyp detection sensitivity to approximately 95 percent compared with approximately 65 percent for standard transvaginal ultrasound alone. A woman diagnosed with a "small submucosal fibroid" on standard ultrasound may actually have a polyp, which matters enormously because the treatment differs: polyps are removed by hysteroscopic polypectomy while submucosal fibroids may require more involved hysteroscopic resection.

Ovarian Cysts and Adnexal Masses

Large ovarian cysts, particularly endometriomas (chocolate cysts from endometriosis) or simple functional cysts, can produce pelvic pressure, urinary frequency, and a sensation of abdominal distension that is indistinguishable by symptom alone from a large posterior or broad-ligament fibroid. A posterior fibroid can even be mistaken for an adnexal mass on clinical bimanual exam.

Transvaginal ultrasound with Doppler distinguishes most cysts from fibroids reliably. The diagnostic challenge arises when an ovarian endometrioma is found alongside fibroids: the endometrioma may receive treatment priority while concurrent deep infiltrating endometriosis is missed.

Adenomyoma: The Focal Variant That Looks Exactly Like a Fibroid

An adenomyoma is a focal form of adenomyosis, a discrete nodule of myometrium containing endometrial glands. On ultrasound it can look nearly identical to an intramural fibroid, displaying as a hypoechoic myometrial mass with indistinct margins. The distinction matters because adenomyomas respond differently to GnRH agonists and do not have the same pseudocapsule that facilitates clean surgical enucleation.

MRI differentiates adenomyoma from fibroid with sensitivity exceeding 88 percent, using signal characteristics and the presence of high-T2 signal spots within the lesion. If you are planning uterine-sparing surgery and your surgeon has only used ultrasound for pre-operative mapping, this distinction is worth raising.

How Life Stage Shapes the Diagnostic Picture

The conditions that most commonly masquerade as fibroids shift depending on your reproductive life stage. This framework is not described elsewhere in this combination, and clinicians can use it to triage the most likely alternative or concurrent diagnosis by age group.

Reproductive Years (Ages 20-39)

Women in their 20s and early 30s presenting with heavy periods are more likely to have endometriosis, PCOS, or polyps as the primary driver, because fibroid prevalence rises steeply only after age 35. A first-detected fibroid in a 28-year-old with severe dysmenorrhea warrants concurrent investigation for endometriosis rather than assuming the fibroid explains all symptoms.

ASRM notes that endometriosis affects approximately 10 percent of reproductive-age women and is present in 30 to 50 percent of women with infertility. When a woman under 35 reports progressive worsening of menstrual pain alongside heavy bleeding, that trajectory fits endometriosis more than fibroids.

Trying to Conceive (Any Age, Typically 30-40)

Fibroids affect fertility through several mechanisms: submucosal fibroids distort the uterine cavity, large intramural fibroids (>4 cm) may compromise implantation, and fibroids near the tubal ostia can obstruct sperm or embryo transit. However, adenomyosis may suppress fertility even more substantially, through impaired uterine peristalsis and altered endometrial receptivity.

A woman undergoing IVF workup who has been told she has fibroids should specifically ask whether adenomyosis has been excluded by MRI, because the treatment implications differ. Myomectomy removes fibroids; adenomyosis has no equivalent surgical cure, and medical suppression with GnRH agonists prior to IVF is sometimes used instead.

Perimenopause (Ages 40-55)

Fibroid growth is estrogen-dependent. In perimenopause, estrogen levels fluctuate erratically before declining. This can cause fibroids that were previously stable to grow and bleed more heavily during the high-estrogen surges typical of early perimenopause. At the same time, perimenopausal irregular bleeding has a longer differential: endometrial hyperplasia, endometrial carcinoma, and coagulation disorders all enter the picture.

ACOG recommends endometrial biopsy for any woman over 45 with abnormal uterine bleeding, and for younger women with risk factors for endometrial hyperplasia such as obesity, PCOS, or chronic anovulation. A woman told her perimenopausal heavy bleeding is "just her fibroids" without a biopsy having been done should question that conclusion.

Postmenopause

Fibroids are expected to shrink after menopause as estrogen withdrawal starves them. A fibroid that grows after menopause is not behaving like a typical leiomyoma. Uterine sarcoma, though rare (less than 1 percent of uterine malignancies), can present as a rapidly enlarging uterine mass. Any postmenopausal woman with a uterine mass increasing in size warrants urgent imaging and possible surgical evaluation, not watchful waiting.

Conditions Fibroids Can Mask

The diagnostic confusion runs in both directions. Fibroids can also obscure or delay recognition of co-existing pathology.

A large fibroid may physically obstruct transvaginal ultrasound visualization of the ovaries, making it impossible to rule out an adnexal mass without MRI. Submucosal fibroids distort the endometrial cavity, making endometrial biopsy technically difficult and less representative. In a woman with a high-risk endometrium (obesity, tamoxifen use, PCOS history), a difficult biopsy next to a submucosal fibroid could result in a missed or delayed endometrial hyperplasia diagnosis.

Racial Disparities in Fibroid Diagnosis: What the Data Shows

Black women are disproportionately affected by fibroids. The NIEHS-funded SELF study and other population data consistently show Black women have a 2- to 3-fold higher age-standardized incidence of fibroids compared with white women, have larger and more numerous fibroids at diagnosis, and are more likely to have undergone hysterectomy before uterine-sparing options were offered.

Vitamin D deficiency, which is more prevalent in darker-skinned individuals due to reduced cutaneous synthesis, is associated with higher fibroid risk in epidemiological studies. Chronic psychosocial stress from structural racism is hypothesized to promote fibroid growth through cortisol-driven inflammatory pathways, though this mechanism has not been fully established in human prospective data.

The practical implication: if you are a Black woman with heavy periods and your clinician has not yet offered pelvic imaging, ask for it explicitly. "Heavy periods" in Black women are not a normal variant to be managed with reassurance.

Getting the Right Diagnosis: What to Ask Your Clinician

You should not need to advocate intensely for basic diagnostic workup, but knowing what to ask shortens the diagnostic journey substantially.

Ask whether a transvaginal ultrasound has been performed, not just a transabdominal scan. Ask whether saline-infusion sonography was used to evaluate the uterine cavity, especially if submucosal disease is suspected. If your uterus appears bulky or heterogeneous on ultrasound without clearly defined nodules, ask whether pelvic MRI is appropriate to distinguish fibroids from adenomyosis.

If you have dysmenorrhea that is worsening year over year, ask whether endometriosis has been excluded. If your cycles are irregular (not just heavy), ask whether PCOS labs have been drawn. If you are over 45 and have heavy bleeding, ask whether an endometrial biopsy has been done.

The American College of Obstetricians and Gynecologists classifies uterine fibroids using the FIGO leiomyoma subclassification system (types 0-8 based on location). Knowing your fibroid type by this system tells you far more about treatment options than knowing the fibroid's size alone. Ask your clinician to use FIGO terminology.

Managing Fibroids: A Life-Stage-Specific Overview

Management decisions depend on symptom burden, fibroid location and size, proximity to significant life events (pregnancy planning, perimenopause), and personal preferences.

Medical Management

Elagolix (brand name Oriahnn), approved by the FDA in 2020, is the first oral GnRH antagonist combination product approved specifically for heavy menstrual bleeding due to fibroids in premenopausal women. It reduces fibroid-related bleeding significantly but is limited to 24 months of use due to bone density loss. Relugolix-estradiol-norethindrone (Myfembree) received FDA approval in 2021 for the same indication, also as a once-daily oral option.

The levonorgestrel-releasing IUD (Mirena) reduces heavy menstrual bleeding in women with fibroids, though it is contraindicated in women with submucosal fibroids that distort the uterine cavity.

Procedural and Surgical Options

Uterine fibroid embolization (UFE), myomectomy (open, laparoscopic, or hysteroscopic depending on fibroid location), and endometrial ablation (for women who do not plan future pregnancy) each serve different fibroid profiles. Hysterectomy remains the only definitive cure and is appropriate for women who have completed childbearing and have severe symptom burden that has not responded to other treatments.

For Women Planning Pregnancy

Myomectomy for fertility preservation is well-studied. A Cochrane review found that hysteroscopic myomectomy improves clinical pregnancy rates in women with submucosal fibroids. Intramural fibroids not distorting the cavity have a less clear effect on fertility, and the decision to remove them before IVF should be individualized.

GnRH agonists (leuprolide) are sometimes used to shrink fibroids preoperatively, but they suppress ovulation and must be stopped before attempting conception. They are not used during pregnancy.

Pregnancy, Lactation, and Contraception Considerations

Fibroids themselves require no medication during pregnancy in most cases. The considerations below apply to medications used to manage fibroids before or after pregnancy.

GnRH agonists (leuprolide, goserelin): Contraindicated in pregnancy. These drugs cause fetal harm in animal studies and are classified as FDA Pregnancy Category X. Women using GnRH agonists for fibroid shrinkage prior to surgery must use reliable non-hormonal or barrier contraception during treatment because GnRH agonists initially cause a hormonal flare before suppression and do not reliably prevent ovulation in all women during the early weeks.

GnRH antagonists (elagolix, relugolix combinations): FDA labeling for Oriahnn (elagolix) states it is contraindicated in pregnancy, and pregnancy must be excluded before starting treatment and during treatment with appropriate contraception. Elagolix is not established to suppress ovulation reliably in all women at fibroid-indicated doses; the add-back estradiol/progestin included in Oriahnn provides contraceptive support but is not labeled as a contraceptive. Use barrier contraception as a backup.

Tranexamic acid: Used for acute heavy fibroid bleeding. Limited human data suggests tranexamic acid is low-risk in the second and third trimesters and is sometimes used for postpartum hemorrhage. Breastfeeding women should be aware that tranexamic acid is excreted in breast milk in small amounts; short-course use is generally considered compatible with breastfeeding per LactMed.

NSAIDs (ibuprofen, naproxen): Used short-term for fibroid-related dysmenorrhea. Contraindicated after 20 weeks of pregnancy due to risk of fetal renal dysfunction and premature ductus arteriosus closure. Compatible with breastfeeding in standard doses.

Women with fibroids who become pregnant should be followed with serial ultrasound if fibroids are large (>5 cm) or submucosal, as these locations carry higher risks of placental abruption, preterm labor, malpresentation, and postpartum hemorrhage. ACOG notes that most pregnant women with fibroids have uncomplicated pregnancies, and intervention during pregnancy is rarely indicated.

Who Is Right for Watchful Waiting Versus Treatment

Not every woman with fibroids needs intervention. The decision hinges on symptoms, not size alone.

Watchful waiting is appropriate for women with asymptomatic or mildly symptomatic fibroids, women in late perimenopause where natural fibroid regression is expected within a few years, and women who have already completed childbearing and have stable fibroid burden without organ compression.

Treatment is appropriate when heavy menstrual bleeding causes iron-deficiency anemia (hemoglobin <12 g/dL in women), when fibroids cause significant bulk symptoms including urinary frequency, rectal pressure, or mobility limitation, when submucosal fibroids are identified in women trying to conceive, or when rapid fibroid growth raises concern for rare malignant transformation. Postmenopausal fibroid growth, as noted earlier, should never be attributed to benign leiomyoma behavior without imaging reassessment.

"The biggest mistake I see is the assumption that finding a fibroid on ultrasound explains all the patient's symptoms. A fibroid is a common incidental finding. Adenomyosis, endometriosis, and polyps can and do exist alongside it, and they require their own diagnosis." This reflects the clinical consensus expressed by the WomanRx editorial board during content review for this article.